Drawing for JP JAZZ PHARMACEUTICALS

USPTO serial 88223219

JP JAZZ PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 5935365Status 702Registered
Filing date
Status date
Registration date
Dec 17, 2019
Examiner
LEE, JEANIE H
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with JP JAZZ PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael Olsen

Michael Olsen Winthrop & Weinstine, P.A.225 SOUTH 6TH STREET, SUITE 3500MINNEAPOLIS, MN 55402United States

Goods and services

ClassDescriptionStatusFirst use
005House mark for a line of pharmaceuticals for the treatment, management and prevention of cancer, psychiatric diseases and disorders, central nervous system conditions, sleep disorders, narcolepsy, schizophrenia, cataplexy, obstructive sleep apnea, and for use in oncological and hematological diseases and disorders; Pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for use in oncology and hematology; pharmaceutical preparations for the treatment and management of neurological, psychiatric, and sleep conditions, diseases, and disorders; pharmaceutical preparations for the treatment and management of cancer, cataplexy, excessive daytime sleepiness, liver disease, narcolepsy, obstructive sleep apnea, and schizophreniaACTIVESep 8, 2004

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 10, 2026NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Feb 18, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Feb 18, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Feb 18, 2026A7OKAMENDMENT UNDER SECTION 7 - PROCESSED—
Feb 13, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 11, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 11, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 11, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 11, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 11, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 11, 2025ES7RTEAS SECTION 7 REQUEST RECEIVED—
Nov 11, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Dec 17, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 26, 2021ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Dec 17, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 1, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 1, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 11, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 27, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 2, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 1, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 1, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 15, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 15, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 25, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 25, 2019COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 15, 2019CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
Mar 15, 2019ALIEASSIGNED TO LIE—
Mar 14, 2019GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 14, 2019GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 14, 2019CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Mar 7, 2019DOCKASSIGNED TO EXAMINER—
Jan 3, 2019MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jan 2, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 13, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance